Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel 5-HT2 receptor ligands described by Vernalis for use particularly in obesity

Sep. 18, 2000

Novel treatments for obesity under study at Lilly

Sep. 15, 2000

Important new approval obtained for Actos

Sep. 15, 2000

Male osteoporosis treated effectively with alendronate in two-year study

Sep. 15, 2000

Oxygent reduces the need for donor blood in phase III trial

Sep. 14, 2000

Gaucher's disease treatment shows continued efficacy after 18 months

Sep. 13, 2000

Buccal formulation of insulin will be developed by Lilly and Generex

Sep. 13, 2000

Benzimidazoles useful as GH mimetics claimed by former P&U

Sep. 12, 2000

Inhale and Lilly reinitiate development of inhalable Forteo; discontinue other program

Sep. 8, 2000

New discoveries in the field of NPY antagonists presented by RWJ at ACS meeting

Sep. 8, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...